EPISODE · Jun 17, 2025 · 8 MIN
Enlivex CEO on Revolutionizing Osteoarthritis Therapy with Allocetra™ | Investor Deep Dive
from Small Stocks, Big Money · host RedChip Companies
Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more.
What this episode covers
Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more.
NOW PLAYING
Enlivex CEO on Revolutionizing Osteoarthritis Therapy with Allocetra™ | Investor Deep Dive
No transcript for this episode yet
Similar Episodes
Apr 29, 2025 ·12m
Apr 27, 2025 ·11m
Apr 24, 2025 ·11m
Apr 22, 2025 ·14m
Apr 22, 2025 ·32m
Feb 27, 2025 ·0m